Dr. Mesa on the Potential Utility of CAR T-Cell Therapy in MPNs | OncLive

Dr. Mesa on the Potential Utility of CAR T-Cell Therapy in MPNs

August 3, 2020

Ruben A. Mesa, MD, discusses the potential utility of CAR T-​cell ​therapy in myeloproliferative neoplasms.

Ruben A. Mesa, MD, director of the Mays Cancer Center at UT Health San Antonio MD Anderson Cancer Center, discusses the potential utility of CAR T-​cell ​therapy in myeloproliferative neoplasms (MPNs).

In recent years, cellular therapy has evolved rapidly in lymphoid malignancies, especially in lymphoma and ​multiple myeloma, says Mesa.

Notably, at the Institutional Perspectives in Cancer webinar on Leukemia and Lymphoma, Paul ​J. Shaughnessy, MD, of Methodist Hospital, expanded on these data and provided insight on future directions of CAR T-cell therapy ​in hematologic malignancies.

The utility of cellular-based therapy, in both hematologic and non-hematologic malignancies, has sparked great interest ​across oncology. Encouraging data suggest CAR T-cell therapy may soon find a place in the MPNs space, ​concludes Mesa.


x